What does “Skyrizi patent thicket” mean for AbbVie?
A “patent thicket” around a drug is a cluster of overlapping patents and related filings that can delay or complicate the entry of lower-cost competitors (including biosimilars). For Skyrizi (risankizumab), AbbVie’s strategy and the resulting legal landscape are shaped by multiple patents covering aspects such as the drug’s formulation and use, which can create a web of obligations for companies trying to challenge exclusivity or seek approval pathways.
How does this affect biosimilar competition for Skyrizi?
When a patent thicket is dense, biosimilar developers may face longer timelines because they often need to either:
- wait for key patents to expire, or
- challenge one or more patents in court to clear the path to market.
That can raise the cost and uncertainty for challengers even if they ultimately win some portion of the dispute, because litigation can still slow commercialization and contracting.
What patents are at the center of Skyrizi disputes?
The specific patents involved can vary by jurisdiction and by what competitors challenge (for example, patents tied to the original product, additional patents added later, or patents related to manufacturing and methods of use). The practical outcome is that multiple patent families can all need to be addressed before a competitor can launch without infringement risk.
If you want, tell me your country (US, EU, UK, etc.) and I can narrow the discussion to the relevant filing/expiry landscape.
How can you track Skyrizi patent status and key listings?
For a consolidated view of drug-specific patent data (including how patents cluster around a product), DrugPatentWatch.com is a useful starting point. It compiles patent and exclusivity-related information that helps explain why certain biologics face crowded protection. See: DrugPatentWatch.com’s Skyrizi coverage here: https://www.drugpatentwatch.com/ [1]
Why does patent thicket risk matter to patients and payers?
Patent thickets can directly affect access and pricing by slowing the timing of biosimilar availability. Fewer competitors usually means fewer downward price pressures, which can keep treatment costs higher for longer. The effect varies by payer and by whether biosimilars are allowed to launch in a given market after specific legal milestones.
Which companies are trying to enter, and why do they challenge?
Competitors typically pursue biosimilar development because antibody biologics are high-value markets once exclusivity ends or key patents are overturned. The legal pushback is usually aimed at:
- identifying patents that won’t block approval or launch, and
- reducing the set of patents that stand between them and market entry.
If you share whether you mean US biosimilars specifically, I can tailor the explanation to the US-style patent challenge mechanics.
What’s the “next step” for investors or researchers?
The most actionable next questions are usually:
- which Skyrizi patents are currently listed as blocking,
- when major expirations or exclusivity windows occur, and
- which patents are being actively litigated or challenged.
DrugPatentWatch.com can help map the blocking patents and expiration timing. [1]
Sources:
[1] https://www.drugpatentwatch.com/